Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.25 USD | 0.00% | -3.12% | +5.98% |
02:31pm | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
May. 09 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Financials (USD)
Sales 2024 * | 562K | Sales 2025 * | 7.36M | Capitalization | 93.41M |
---|---|---|---|---|---|
Net income 2024 * | -41M | Net income 2025 * | -42M | EV / Sales 2024 * | 128 x |
Net cash position 2024 * | 21.26M | Net Debt 2025 * | 12.33M | EV / Sales 2025 * | 14.4 x |
P/E ratio 2024 * |
-2.21
x | P/E ratio 2025 * |
-2.16
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.54% |
Latest transcript on Clearside Biomedical, Inc.
1 day | +1.20% | ||
1 week | -3.12% | ||
Current month | -1.59% | ||
1 month | -3.88% | ||
3 months | -4.62% | ||
6 months | +27.84% | ||
Current year | +5.98% |
Managers | Title | Age | Since |
---|---|---|---|
George Lasezkay
CEO | Chief Executive Officer | 72 | 17-08-07 |
Charles Deignan
DFI | Director of Finance/CFO | 59 | 11-12-31 |
Susan L. Coultas
CTO | Chief Tech/Sci/R&D Officer | - | 22-06-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Lasezkay
CEO | Chief Executive Officer | 72 | 17-08-07 |
Jeffrey Edwards
BRD | Director/Board Member | 64 | 18-09-25 |
Christy Shaffer
BRD | Director/Board Member | 66 | 11-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 1.25 | 0.00% | 51 353 |
24-05-10 | 1.25 | -7.41% | 286,328 |
24-05-09 | 1.35 | +6.30% | 136,371 |
24-05-08 | 1.27 | -0.78% | 162,224 |
24-05-07 | 1.28 | 0.00% | 197,243 |
Delayed Quote Nasdaq, May 13, 2024 at 10:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.98% | 93.41M | |
+4.95% | 109B | |
+11.29% | 105B | |
+0.32% | 22.25B | |
-12.24% | 22.09B | |
-8.00% | 18.68B | |
-36.52% | 17.58B | |
-10.50% | 16.85B | |
+4.78% | 13.76B | |
+35.77% | 12.46B |
- Stock Market
- Equities
- CLSD Stock